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Abstract:With the recent transposition of Directive 2010/53/EU into the transplant regulation of EU Member States, the time is
right to have a closer look at its implications for living organ donation practice. We first discuss the relevance of the Action Plan
which forms the basis for the policy of the European Commission in the field of organ donation and transplantation. We then
analyze the impact of Directive 2010/53/EU which was adopted to support the implementation of the Priority Actions set out in
the Action Plan. We more specifically focus on the obligations of transplant centers engaged in living organ donation and highlight
their significance for clinical practice. Finally, we point out some strengths and weaknesses of the Directive in addressing living
organ donation.(Transplantation 2015;00: 00–00)Organ donation and transplantation first entered theagenda of the European Union in 1997 with the adop-
tion of the Treaty of Amsterdam.1 InApril 2007, the European
Commission issued a Communication on Organ Donation
and Transplantation, with the intention to respond to major
challenges in the field of organ transplantation. It proposed a
dual mechanism of action: an Action Plan aimed at enhanc-
ing cooperation between EUMember States and a binding le-
gal instrument which would contain basic principles on the
quality and safety of organs intended for transplantation.2
Following this Communication, the European Commission
issued itsAction Plan onOrganDonation and Transplantation
(2009–2015) in December 2008. It is running for a 6-year pe-
riod and is scheduled to end in 2015. The aim of the Action
Plan is to strengthen cooperation between EUMember States
to increase the availability of organs, enhance the efficiencyReceived 25 April 2014. Revision requested 21 May 2014.
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the quality and safety of organs.
The Action Plan identifies the promotion of living organ
donation in EUMember States as one of the Priority Actions
for increasing organ availability. It suggests a double strategy
to increase living organ donation under conditions of safety.
First, it proposes to exchange best practices on living organ do-
nation between Member States. The final objective is to de-
velop a toolbox which collects Member States' expertise and
experiences in setting up living donation programmes and
provides tools for the selection, evaluation, and protection
of donors and for the collection of information on the conse-
quences of living donation.3
Second, theAction Plan advocates the establishment of na-
tional registries of living organ donors to facilitate monitor-
ing and follow-up. To this aim, the European Commission
is cofunding a project intended to assist in the design and
management of these registries and to set up a model forKristof Van Assche acknowledges financial support from the Flemish Fund for
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TABLE 1.
Obligations of transplant centers under Directive 2010/53/EU
Medical assessment of
prospective living donors
Article 7
Preamble, para 12
Minimization of risks to prospective
living donors
Article 15, paras 1 & 2
Obtaining valid consent or authorization Article 14
Preamble, para 23
Maintaining confidentiality and anonymity Article 16
Preamble, para 22
Providing adequate follow-up of living donors Article 15, para 4
Collecting data on living donation Article 15, paras 3 & 4
Article 18, para 1
Identifying, reporting and managing unintended
and unexpected situations
Article 11
Transmitting data allowing traceability of organs Article 10
2 Transplantation ■ Month 2015 ■ Volume 00 ■ Number 00 www.transplantjournal.comsupranational data sharing, resulting in a European living do-
nor “Registry of Registries.”4 It is assumed that the infor-
mation to be compiled with the aid of these systems will
contribute to the improvement of living donor care in the
EuropeanUnion and to the harmonization of existing regula-
tions in the field.
In July 2010,Directive 2010/53/EU on standards of qual-
ity and safety of human organs intended for transplantation
was adopted to support the implementation of the Action
Plan. The Directive requires EU Member States to adopt
minimum standards with regard to key aspects of organ
donation and transplantation. In addition, every Member
State has to designate a competent authority—as a rule,
this task is assumed by the appropriate national transplant
organization—responsible for establishing a national frame-
work for quality and safety of organs and for implementing
the Directive. The main purpose is to improve the quality
and safety of organs intended for transplantation, which
should lead to better screening, a better match, reduced risks
for recipients and living donors, and less organ failure.
As a result of these regulatory and organizational mea-
sures, the Directive will have a profound harmonizing effect
on transplant practice in the 28 Member States of the Euro-
pean Union. Moreover because many other European coun-
tries (e.g., countries candidate to accession to the European
Union and countries involved in international organ ex-
change with EUMember States) are in the process of aligning
their transplant regulation with EU policy, the impact of the
Directive extends far beyond EU borders. Its provisions had
to be transposed in the domestic law of EU Member States
by 27 August 2012.5 Notwithstanding this strict deadline,
several EU Member States have only very recently finalised
the transposition process. Therefore, now is the right time
to analyse the relevance of the Directive for living organ do-
nation practice.
To this end, the Ethical, Legal and Psychosocial Aspects of
Organ Transplantation (ELPAT) section of the European So-
ciety for Organ instituted a working group on this topic. The
ELPAT is a European platform that brings together profes-
sionals, such as transplant surgeons, transplant coordinators,
specialist nurses, (bio-)ethicists, lawyers, psychologists, phy-
sicians, sociologists, anthropologists, policy makers, and
criminologists, to debate and stimulate research on the issues
surrounding transplantation. This article contains the find-
ings of the ELPAT working group on the estimated impact,
strengths and weaknesses of Directive 2010/53/EU.
OBLIGATIONS UNDER DIRECTIVE 2010/53/EU AND
THEIR ESTIMATED IMPACT
In what follows, we will briefly highlight the provisions
which impose specific obligations on transplant centers and
health care professionals engaged in living organ donation.
An overview of these obligations is presented in Table 1. At
the same time, we will assess the estimated impact of these
obligations on clinical practice. An overview of the clinical
practice at the time of the implementation of the Directive
is presented in Table 2.
Medical Assessment of Prospective Living Donors and
Minimization of Risks
The Directive requires prospective living donors to un-
dergo a thorough medical screening to determine possibleCopyright © 2015 Wolters Kluwer Health, Inc. Unauhealth risks for donor and recipient and the suitability of
the organ for transplantation. This assessment should be per-
formed by qualified health care professionals on the basis of
the prospective donor's medical history, an interview, and a
physical examination and complementary tests.
In addition, theDirective requires that the highest possible
protection of living donors should be ensured. As a result, liv-
ing organ donation should not be allowed if this would pres-
ent unreasonable medical risks and the procurement itself
should be performed in a manner that minimises the risk to
the donor.
Data from transplant centers indicate that these are gen-
eral principles that are already well established and univer-
sally applied. Differences in practice between transplant
centers concern more technical aspects, such as accepting cer-
tain medical conditions as a contraindication for living dona-
tion and the possible additional requirement of psychosocial
screening of prospective donors. Although similar absolute
contraindications for donation are reported in all countries,
it should be noted that no precise regulations on donor
screening exist at international level and that there is a certain
lack of evidence regardingmost of the (relative) contraindica-
tions for living kidney donation, as reflected in the relevant
guidelines.7 Because of the general nature of its provisions
on medical assessment and risk minimization, the Directive
will not have much added value in this respect.
Obtaining Valid Consent or Authorization
TheDirective states that the procurement of an organ from
a living person is only allowed after all requirements relating
to consent or authorization, in force in the Member State
concerned, have been met. It is specified that consent or au-
thorization should be explicit, free and based on information
about, at least, the purpose and nature of the donation and its
consequences and risks.
These provisions do not go beyond what is recommended
by international ethical guidelines and legal instruments.
Moreover, data from transplant centers indicate that the need
to obtain valid consent or authorization is a long-standing,
essential rule of transplant practice. Differences in practice
concern the modalities of the consent (e.g., written or verbal)
and the extent of the information to be provided. Since thethorized reproduction of this article is prohibited.
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4 Transplantation ■ Month 2015 ■ Volume 00 ■ Number 00 www.transplantjournal.comDirective contains no precise provisions in this regard, it will
not require a change of practice.
However, confronted with the requirement to implement
theDirective, several EUMember States still seem to have taken
the opportunity to strengthen their information and consent
regulations. For instance, in Belgium and Luxembourg, the
fulfilment of consent requirements will henceforth need to
be assessed by a pluridisciplinary team and in France and
Greece the range of information to be provided to prospec-
tive living donors is broadened.
Maintaining Confidentiality and Anonymity
The Directive requires that strict confidentiality rules and
security measures are put in place for the protection of the
personal data of donors and recipients. It is clarified that, in
cases of unspecified living donation (i.e. where the living do-
nor and the recipient do not know each other) and specified
indirect donation (i.e. when a willing but incompatible per-
son donates to an unknown recipient within an exchange
or sharing scheme, or for a higher position on the waiting
list for his or her intended recipient), transplant teams
should not disclose the identity of the recipient to the donor
and vice versa.8
However, the requirement of maintaining anonymity may
be waived under 2 conditions. First, when there is a medical
need to make such information available to donors or recip-
ients (e.g., in the case of transmission of a communicable dis-
ease). Second, when revocation of anonymity is allowed
under domestic law and both the donor and the recipient
have given their explicit consent. In practice, revocation of
anonymity before transplantation is not allowed in any EU
Member State and revocation of anonymity after transplan-
tation currently seems only allowed in the United Kingdom,
subject to the mutual consent of both parties.9
With regard to confidentiality and anonymity, the Direc-
tive is only reiterating general principles that have been put
forward by binding international data protection instru-
ments.10 Since these principles have already been applied to
the transplant setting by all EUMember States, the estimated
impact of the Directive on current data protection practice
will remain very limited.
Follow-up of Living Donors
TheDirective requires that one should consider providing
living donors with adequate follow-up. Data from transplant
centers indicate that donor follow-up is currently already
being offered in all living kidney donation centers in
Northwestern and Mediterranean Europe. In almost half
of these centers, follow-up is even life-long. In contrast,
only 40% of Eastern European centers currently offer
follow-up to living donors, and this follow-up is very fre-
quently limited in time.
Regulations across EU Member States vary widely, not
only with regard to the need to offer follow-up, but also with
regard to its modalities (e.g., intervals of the medical check-
ups, individualization of the aftercare plan, need to alert do-
nors to the importance of follow-up). Although theDirective
stresses the crucial importance of offering follow-up to living
donors in those EU regions where this is currently absent,
its impact will likely be rather limited. The main reason is
that, in contrast to the other obligations set forth in theDirec-
tive, the provisions on donor follow-up are not binding.Copyright © 2015 Wolters Kluwer Health, Inc. UnauMoreover, the Directive does not contain more specific re-
quirements that would prompt EU Member States to recon-
sider the modalities of their domestic regulations of donor
follow-up.
Collecting Data on Living Donation
The main organizational innovation of the Directive in-
volves the establishment at the level of each Member State
of central registries, maintained and administered by the na-
tional competent authority. One of these registries is the na-
tional living donor registry, which compiles data directly
related to living organ donation. Data from transplant cen-
ters indicate that donor registries are already in place in al-
most all living kidney donation centers in Northwestern
andMediterranean Europe and inmore than 80%of Eastern
European centers. However, most of these registries are
administered by the transplant centers themselves, with
living donor registries at national level very frequently
not yet operational.11
National living donor registries will have to collect 2 types
of data, which transplant centers are required to systemati-
cally provide. The first type of data concerns aggregated
numbers of living donors and the types and quantities of or-
gans procured and transplanted, or otherwise disposed of.
On the basis of these data, the national competent authority
has to draw up an annual report and make it publicly acces-
sible. The second type relates to relevant post-transplantation
data. During follow-up of living donors and the recipients
of their organs, transplant centers are required to collect
and to report all data relevant for the quality and safety
of the transplanted organs. These data will mainly focus
on mortality and morbidity but may include a variety of
additional data. What data will need to be compiled and
transmitted will depend on the guidance issued by the na-
tional competent authority.
By requiring that certain types of data should be collected
and then centralised at national level, the Directive will in
many EU Member States result in a major shift in practice.
Moreover, with plans being developed at European level to
harmonise national living donor registries and to establish
an overarching European living donor registry, centralization
of relevant data will further increase. In this way, transplant
centers and policy makers will have access to an enormous
amount of information that may greatly contribute to the im-
provement of living donor care.
Identifying, Reporting, and Managing Unintended and
Unexpected Situations
In addition to collecting data on living donation, theDirec-
tive also requires transplant centers to establish operating
procedures for the identification, reporting and management
of so-called serious adverse events and serious adverse reactions
occurring at any stage of the chain from living organ dona-
tion to transplantation of the organ. Serious adverse events
are undesired and unexpected occurrences that might lead
to the transmission of a communicable disease, to death or
life-threatening, disabling or incapacitating conditions for
the living donor or the recipient of the organ, or which result
in, or prolong, hospitalization or morbidity. Similarly, serious
adverse reactions are unintended responses, including a com-
municable disease, in the living donor or the recipient, thatthorized reproduction of this article is prohibited.
© 2015 Wolters Kluwer 5are fatal or life-threatening, disabling or incapacitating, or
which result in, or prolong, hospitalization or morbidity.
Serious adverse reactions may manifest themselves after
the persons concerned have been discharged from hospital
and as such will constitute relevant post-transplantation data
that will already need to be included in the national living do-
nor registry. Notwithstanding this possibility, important in-
formation concerning serious adverse events and reactions
needs to be transmitted to a central reporting and manage-
ment system put in place by the competent authority. This
system should allow timely notification of any serious ad-
verse event and reaction to the competent authority and to
other transplant centers concerned. In turn, this should trig-
ger operating procedures aimed at managing risks and im-
proving safety measures.
No precise data are available on the extent to which EU
Member States have already put in place operating proce-
dures for the identification, reporting and management of
serious adverse events and reactions. However, the practice
in EU countries where living donation is frequently per-
formed (e.g., The Netherlands, Sweden and UK) indicates
that no official central registration of serious adverse events
and reactions existed prior to the adoption of the Directive.
However, following the implementation of the Directive,
such a central registry is now being established by national
competent authorities, with transplant centers obliged both
to communicate serious adverse events and reactions as they
occur and to issue an annual report. It is clear that by intro-
ducing this kind of obligation, the Directive entails a major
change of practice in EU transplant centers.
Transmitting Data Allowing Traceability of Organs
Apart from a living donor registry and a reporting and
management system for serious adverse events and reactions,
the national competent authority is also required to establish
andmaintain a central system for organ traceability. This sys-
tem should ensure that all organs procured, allocated and
transplanted on their territory can be traced from the donor
to the recipient and vice versa. Traceability allows the alarm
to be raised if serious adverse events or reactions occur and is
therefore crucial for the protection of vital interests of the in-
dividuals concerned.
The data need to be stored for a minimum of 30 years and
have to be systematically provided by transplant centers. The
data concerned include the characterization of the organ, the
identity of the living donor and the recipient, the transplant
centers involved and all relevant information relating to
products and materials coming into contact with the organ.
Although no exact data are available, systems of organ
traceability seem to have been established long before the adop-
tion of the Directive. With, for instance, well-functioning
traceability mechanisms in place at the level of international
organ exchange organizations such as Eurotransplant and
Scandiatransplant, albeit currently not directly dealing with
living donation, the relevance of the Directive in this respect
will be rather limited.
STRENGTHS OF THE DIRECTIVE
The crucial importance of theDirective lies in the require-
ment of establishing, at the national level of each EUMember
State, a very extensive regulatory framework aimed at pro-
tecting living donors and monitoring and improving theCopyright © 2015 Wolters Kluwer Health, Inc. Unauquality and safety of organs (Table 3). When compared to
current practice, the added value is 3-fold.
The Directive encourages transplant centers to systemati-
cally offer donor follow-up where this is not yet provided.
This is mainly relevant for Eastern European transplant cen-
ters but it may also prompt many transplant centers in
Northwestern andMediterranean Europe to reconsider their
follow-up policy so that it is no longer limited in time.
In addition, the Directive requires living donor registries,
which before frequently were only administered by the indi-
vidual transplant centers, to be centralized at national level.
By establishing a national living donor registry, which will
be connected to the living donor registries of the other EU
Member States, it will be possible tomore accurately monitor
the extent, long-term outcome and other characteristics of
living organ donation in the EU. Similarly, by centralising
an enormous amount and a greater variety of relevant post-
transplantation data, insights into living donor care may be
significantly improved.
Furthermore, the Directive will result in the implementa-
tion of operating procedures for the identification, reporting
and management of serious adverse events and reactions,
with a central registry to be established at national level. This
will likely lead to better risk assessment and perfecting of
safety measures.
Apart from these aspects, the significance of the Directive
lies in its binding nature. Several of the obligations set forth
in theDirective were previously only recommended by inter-
national ethical guidelines but are now explicitly imposed. In
doing so, theDirectivewill also have a profound harmonising
effect on living organ donation practice in the EU.
In sum, it is to be expected that the Directive will succeed
in its goal: improving the quality and safety of organs
intended for transplantation, resulting in better screening, a
better match, reduced risks for donors and recipients, and
less organ failure.
WEAKNESSES OF THE DIRECTIVE
Although the EU Directive 2010/53/EU has to be
applauded as a crucial instrument, some of the practical im-
plications of the implementation of its provisions remain un-
addressed. Themain concerns relate to themajor investments
that are required to successfully deploy the quality and safety
framework. The costs of establishing a tightly regulated na-
tional transplantation system, responsible for the supervision
of transplant activities, the accreditation and control of trans-
plantation centers and the maintenance of 3 distinct natio-
nal registries, may prove difficult to shoulder for several EU
Member States.
Similarly, at the level of the transplant centers and individ-
ual health care professionals, the procedures related to audits,
training programmes, follow-up and accurate collection and
reporting of information, may significantly add to the work-
load. In the face of increasing pressure to reduce expenditure
in health care and in hospitals, the implementation of these
requirements of the Directive may prove a real challenge to
some centers.
In addition, in contrast to the level of detail of many of the
more technical provisions, several of the provisions aimed
at protecting living organ donors are very general. With
the exception of registration requirements, these provisions
frequently do not go beyond or even stay well below whatthorized reproduction of this article is prohibited.
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© 2015 Wolters Kluwer 7is recommended by international ethical guidelines and legal
instruments.12 For instance, compared to the recommenda-
tions issued in the Consensus Statement of the Amsterdam
Forum on the Care of the Live Kidney Donor, the Directive
does not require psychosocial evaluation of prospective do-
nors and long-time follow-up of living donors.13 More prob-
lematically, with regard to the requirements for valid consent
of a living donor, theDirective only refers to domestic regula-
tions. Although this approach may be partially explained by
the restricted scope of theDirective, we regret the fact that the
Directive has not even laid out minimal standards that need
to be met in order for the consent of a living donor to be valid
and that the opportunity was not taken to harmonise consent
procedures across EU Member States.14
Moreover, the Directive only requires Member States to
endeavor to carry out the follow-up of living donors,
whereas this requirement is an obligation under most of
the aforementioned international ethical guidelines and legal
instruments. Considering that in many European countries
follow-up is covered by the insurance of either the recipient
or the donor, it would have been a major step forward if
the Directive would in addition have required guaranteed
and life-long follow-up even in the absence of proper private
insurance coverage.
Similarly, the protection of living donors would have been
greatly enhanced if the Directive had required guaranteed
coverage of expenses and loss of income for living donors,
guaranteed compensation in the event of disability or death
of the donor because of complications, and guaranteed trans-
plantation in case living donors become renal insufficient.
Various further proposals have been made in recent times,
aiming to provide nonmonetary rewards to living donors,
for example, the proposal by the Dutch Health Council that
in case a living kidney donor becomes in need of a kidney
transplant, he/she should be put on top of the waiting list
for a deceased donor kidney.15
Finally, the Directive remains very vague with respect to
the sanctions that apply in case of noncompliance. While
transposing the provisions of the Directive into their domes-
tic law, EUMember States are required to lay down rules on
the applicable penalties and to ensure that these penalties are
implemented. However, the Directive merely indicates that
these penalties should be effective, proportionate and dissua-
sive. Although it is provided that EU Member States should
notify the European Commission of the measures taken, the
lack of supervision and harmonization of sanctions may be
a cause for concern.CONCLUSIONS
Directive 2010/53/EU is a very important legal instrument
with major implications for living organ donation practice.
We have identified 8 obligations to be addressed by trans-
plant centers engaged in living organ donation. Several of
these obligations reiterate in a general way what is already
recommended by international ethical guidelines and other
legal instruments. In this respect, the added value of the
Directive lies in its binding nature and harmonizing effects
on living organ donation practice.
The main significance of the Directive, when compared
to other international legal instruments, is situated in its re-
quirement to establish at the national level of each MemberCopyright © 2015 Wolters Kluwer Health, Inc. UnauState 3 central registries aimed at monitoring and improving
the quality and safety of organs. As these registries are grad-
ually being deployed, transplant centers will need to system-
atically report a wide variety of data on living organ
donation. These and other obligations faced by health care
professionals may result in major changes in practice.
In addition, authorities and health care professionals will
need to become familiar with the meaning and implications
of the new concepts introduced by theDirective (e.g., serious
adverse events and reactions, traceability, donor characteri-
zation, confidentiality of data). Furthermore, new duties
may arise as a result of regular audits to be performed by
competent authorities, the need for periodic training and
the commitment to adequately organise and provide follow-
up of living donors.
The weaknesses of the Directive are related to the signifi-
cant costs and efforts required for the implementation of its
provisions and to its failure to elaborate more detailed stan-
dards and procedural safeguards aimed at enhancing the pro-
tection of living donors.
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